ORPH Open Orphan

EQS-News: hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal

EQS-News: hVIVO PLC
hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal

14.11.2022 / 12:14 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: hVIVO PLC
United States
ISIN: GB00B9275X97
EQS News ID: 1486921

 
End of News EQS News Service

1486921  14.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1486921&application_name=news&site_id=research_pool
EN
14/11/2022

Underlying

ORPHOpen Orphan

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Open Orphan

Daniel Appiah
  • Daniel Appiah
ORPH OPEN ORPHAN

Expansion to sustain growth with boosted capacity

hVIVO is establishing a new facility in the Canary Wharf life sciences hub, London. This will increase its quarantine bed capacity and provide greater flexibility to meet anticipated higher demand for its human challenge clinical trial services. The new site, which management notes is mostly funded

09/05/23 September 5, 2023 1 EN
 PRESS RELEASE
Free
ORPH OPEN ORPHAN

EQS-News: hVIVO hails growing contract values after winning £13.6mln R...

EQS-News: hVIVO PLC hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal 14.11.2022 / 12:14 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactiveProactive UK Ltd 3News Source: News Direct 14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -n...

November 14, 2022 1 EN
Daniel Appiah
  • Daniel Appiah
ORPH OPEN ORPHAN

Open Orphan: Booming orders show market leadership

Open Orphan (which will be rebranded hVIVO starting 26 October) is a growing specialist contract research organisation (CRO) with a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). It has reported in the H1FY22 results revenues of

09/16/22 September 16, 2022 1 EN
Daniel Appiah
  • Daniel Appiah
ORPH OPEN ORPHAN

Open Orphan delivering on growth expectations

Open Orphan is a growing specialist contract research organisation (CRO) with a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). High demand for hVIVO's challenge studies in respiratory infections and infectious diseases, helped t

06/21/22 June 21, 2022 1 EN
John Savin PhD ... (+2)
  • John Savin PhD
  • Robin Davison
ORPH OPEN ORPHAN

Open Orphan: profitable outlook for 2022

In just over two years Open Orphan (Open), a rapidly growing specialist contract research organisation (CRO), has built a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). High demand for hVIVO's challenge studies in respiratory in

02/17/22 February 17, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch